港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维立志博-B

67.100

+32.10091.71%

成交量：3,311.83万

成交额：23.49亿

市值：129.50亿

市盈率：-38.90

高：79.600

开：72.400

低：67.100

收：35.000

数据加载中...

总览公司新闻公告

136亿！南京独角兽IPO，开盘大涨120%！

维立志博-B(09887)：独立非执行董事杜季柳获委任为提名委员会的成员

中信证券保荐维立志博完成今年以来超额认购倍数最高的港股18A IPO

中信证券发布

港股综述｜半导体板块逆势走强，华虹半导体涨超9%；维立志博-B首挂大涨近92%

老虎资讯综合

港股收评：三大指数均跌超1%，科技金融低迷，半导体股午后异动大幅拉升

一个医药IPO大涨100%

今天南京独角兽IPO敲钟，大涨100%

市值超135亿！八旬创始人今日敲钟

维立志博登陆港交所，为南京江北新区今年第二家上市企业

港股午评：高位回调！恒指跌1.11%止步5连涨，科技股、金融股低迷

招银国际作为整体协调人、联席全球协调人助力维立志博IPO成功发行并在香港联交所主板挂牌上市

维立志博携4-1BB靶点全球首成药产品在港交所正式挂牌上市

“中国TCE第一股”开盘大涨126%！维立志博正式登陆港交所，多元布局领跑肿瘤免疫治疗2.0时代

独角兽早知道

《股市简讯》中国生物科技公司维立志博香港“首秀”，盘中一度涨127%

异动解读 | 维立志博-B首日挂牌大涨115.71%，创新药企IPO获3494倍超额认购

港股早评：三大指数低开金融股回调有色金属股、水泥股强势

“中国TCE第一股”在港交所挂牌上市，维立志博价值揭秘正当时

新股首日 | 维立志博-B(09887.HK)首挂上市早盘高开近107% 核心产品LBL-024为处于注册临床试验阶段的4-1BB靶向候选药物

新股首日｜维立志博-B大幅高开逾106%，中签一手赚3740港元

老虎资讯综合

一图看懂维立志博IPO

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/09887/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":67.1,"timestamp":1753430887036,"preClose":35,"halted":0,"volume":33118341,"delay":0,"floatShares":148000000,"shares":193000000,"eps":-1.725,"marketStatus":"休市中","change":32.1,"latestTime":"07-25 16:08:07","open":72.4,"high":79.6,"low":67.1,"amount":2349489336,"amplitude":0.357143,"askPrice":67.4,"askSize":100,"bidPrice":67.1,"bidSize":700,"shortable":0,"etf":0,"ttmEps":-1.651777067,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":7,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":35,"openAndCloseTimeList":[[1753407000000,1753416000000],[1753419600000,1753430400000]],"volumeRatio":0,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":148000000,"roa":"--","roe":"--","lyrEps":-1.725,"shares":193000000,"dividePrice":0,"high":79.6,"amplitude":0.357143,"preClose":35,"low":67.1,"week52Low":67.1,"pbRate":"61.40","week52High":79.6,"institutionHeld":0,"latestPrice":67.1,"committee":0.75,"eps":-1.725,"divideRate":0,"volume":33118341,"delay":0,"ttmEps":-1.651777067,"open":72.4,"prevYearClose":35,"prevWeekClose":35,"prevMonthClose":35,"prevQuarterClose":35,"fiveDayClose":35,"twentyDayClose":35,"sixtyDayClose":35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554715440","title":"136亿！南京独角兽IPO，开盘大涨120%！","url":"https://stock-news.laohu8.com/highlight/detail?id=2554715440","media":"创客公社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554715440?lang=zh_cn&edition=fundamental","pubTime":"2025-07-26 15:31","pubTimestamp":1753515067,"startTime":"0","endTime":"0","summary":"7月25日上午，南京维立志博生物科技股份有限公司在香港交易所主板鸣锣上市，发行价为35港元/股，一度上涨超120% 。截至目前，市值达到136亿港元。据悉，这是南京今年第3家上市企业，至此，南京在香港交易所上市的企业数量达32家。园区已上市药品总数达到405件，其中1类新药达6件，医疗器械产品1261个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726153517a464700e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726153517a464700e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554793748","title":"维立志博-B(09887)：独立非执行董事杜季柳获委任为提名委员会的成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2554793748","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554793748?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 22:40","pubTimestamp":1753454430,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，(i)独立非执行董事杜以龙先生不再为公司提名委员会的成员;及(ii)独立非执行董事杜季柳已获委任为提名委员会的成员，自上市日期起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887"],"gpt_icon":0},{"id":"2554907217","title":"中信证券保荐维立志博完成今年以来超额认购倍数最高的港股18A IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2554907217","media":"中信证券发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554907217?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 19:55","pubTimestamp":1753444500,"startTime":"0","endTime":"0","summary":"2025年7月25日，南京维立志博生物科技股份有限公司成功在香港联交所主板上市，基础发行规模1.43亿美元，发售量调整权和超额配售权均悉数行使后，最高发行规模1.89亿美元，中信证券担任联席保荐人、联席整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。本项目也是今年以来融资规模第二大的港股18A IPO项目，至此，中信证券以保荐人身份参与了2022年以来港股市场最大的三单18A IPO项目，项目执行和发行能力获得市场的高度认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726090303a6c26891&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726090303a6c26891&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06030","BK1564","HSTECH","LU1720050803.USD","BK1516","09887","HSCEI","LU1794554557.SGD","BK1147","BK1521"],"gpt_icon":1},{"id":"1135975303","title":"港股综述｜半导体板块逆势走强，华虹半导体涨超9%；维立志博-B首挂大涨近92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135975303","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135975303?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 16:30","pubTimestamp":1753432200,"startTime":"0","endTime":"0","summary":"半导体板块逆势走强，$华虹半导体$涨超9%，$中芯国际$、$上海复旦$涨近5%；机构看好AI和国产化打开成长空间。新股$维立志博-B$首日大幅收涨91.7%；此前公开发售阶段维立志博-B获3494.78倍认购，一手中签率0.27%。海南自贸区板块回调，半导体板块逆势拉升7月25日，A股主要指数集体下跌，沪指跌0.33%报3593点，深证成指跌0.22%，创业板指跌0.23%。全市场超2700股下跌。","market":"sh","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSI","09887","HSTECH","01347"],"gpt_icon":0},{"id":"2554375278","title":"港股收评：三大指数均跌超1%，科技金融低迷，半导体股午后异动大幅拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2554375278","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554375278?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 16:20","pubTimestamp":1753431649,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["601766","BABA","00981","03086","METmain","TTTN","01299","513600","MPNGY","LU","601995","601288","00939","HHImain","01766","82318","01288","JD","01800","601318","MCHmain","01810","MIUmain","MHImain","600030","02833","06655","PAImain","PNGAY","600801","03908","09618","07226","601939","AAGIY","688981","02318","ALBmain","03145","HSImain","01347","06030","HSCEI","YANG","HSI","HSTECH","01024","09887","KSTmain","03690"],"gpt_icon":0},{"id":"2554796486","title":"一个医药IPO大涨100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554796486","media":"投资界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554796486?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 15:33","pubTimestamp":1753428780,"startTime":"0","endTime":"0","summary":"截至目前，市值达到136亿港元。回望过去半年，港股生物医药IPO钟声不断。而报告期内唯一一笔近900万元的收入，来自百济神州。兜兜转转13年，康小强与赖寿鹏终于迎来人生第一个IPO。其核心在研产品HY1001，有望成为国内首个上市的重组人白蛋白药品。随后上周，北芯生命IPO顺利通过审核。科创板之外，港股医药类IPO十分火热。恒瑞医药以98.9亿港元募资额创下近五年最大医药IPO，首日股价涨超25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725154107a462cf13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725154107a462cf13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09939","BK1161","BK1515","09887"],"gpt_icon":1},{"id":"2554431750","title":"今天南京独角兽IPO敲钟，大涨100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554431750","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554431750?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 14:50","pubTimestamp":1753426200,"startTime":"0","endTime":"0","summary":"截至目前，市值达到136亿港元。今天，他们联手IPO敲钟康小强，出生于1961年，于1985年获得湖北医学院学士学位后，进入同济医科大学、北得克萨斯大学深造，并取得硕博学位。早在2015年，维立志博完成天使轮融资，由南京凯元、上海庄钟合计增资33.33万元，作价1000万元。其核心在研产品HY1001，有望成为国内首个上市的重组人白蛋白药品。随后上周，北芯生命IPO顺利通过审核。恒瑞医药以98.9亿港元募资额创下近五年最大医药IPO，首日股价涨超25%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2025-07-25/doc-infhsmty5040283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4202","159982","09887","NCI"],"gpt_icon":1},{"id":"2554796086","title":"市值超135亿！八旬创始人今日敲钟","url":"https://stock-news.laohu8.com/highlight/detail?id=2554796086","media":"猎云网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554796086?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 14:08","pubTimestamp":1753423716,"startTime":"0","endTime":"0","summary":"据悉，维立志博全球发售3686.25万股H股股份，香港公开发售占43.48%，国际发售占56.52%。本次发售中，香港公开发售获大幅超额认购，认购倍数高达3494.78倍，国际发售也获得40.78倍认购。彼时，创始人之一的赖寿鹏已经年过六旬。招股书显示，公司目前拥有14款在研药物，其中6款已进入临床试验阶段，包括核心产品LBL-024和主要产品LBL-034、LBL-033、LBL-007等。从财务数据来看2023年、2024年、2025年一季度分别亏损3.62亿元、3.01亿元及7536.7万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725140846971da715&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725140846971da715&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554796438","title":"维立志博登陆港交所，为南京江北新区今年第二家上市企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2554796438","media":"e公司","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554796438?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 12:26","pubTimestamp":1753417560,"startTime":"0","endTime":"0","summary":"据介绍，LBL-024的首发适应症为肺外神经内分泌癌，针对这一恶性肿瘤，目前临床缺少有效治疗手段。值得一提的是，就在一个月前，南京江北新区企业药捷安康也在港交所鸣锣上市。药企争相上市的背后，是南京江北新区生命健康产业发展如火如荼。截至目前，园区上市药品总数达到405件，其中1类新药达6件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725122808971d7c68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725122808971d7c68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554066758","title":"港股午评：高位回调！恒指跌1.11%止步5连涨，科技股、金融股低迷","url":"https://stock-news.laohu8.com/highlight/detail?id=2554066758","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554066758?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 12:00","pubTimestamp":1753416044,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0048597586.USD","161032","01024","09988","BK4581","89618","HTCD.SI","BK4551","08496","TCHmain","BABA","LU0797268264.HKD","MHImain","ALBmain","HSCEI","HSImain","XIACY","81024","HMTD.SI","03690","HHImain","TTTN","YANG","LU1993786604.SGD","02833","HSI","00700","BIDU","07226","HSTECH","03086","JD","KSTmain","LU1956131251.USD","TSYW.SI","09887","TSLA","MCHmain","METmain","81810","MIUmain","TCEHY","TSLL","LU2226246903.HKD","513600","MPNGY","09618","01810","HXXD.SI"],"gpt_icon":0},{"id":"2554964337","title":"招银国际作为整体协调人、联席全球协调人助力维立志博IPO成功发行并在香港联交所主板挂牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2554964337","media":"招银国际","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554964337?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 10:08","pubTimestamp":1753409286,"startTime":"0","endTime":"0","summary":"交易概述2025年7月25日，南京维立志博生物科技股份有限公司成功在香港联合交易所主板挂牌上市。招银国际担任维立志博在香港IPO的整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。作为招商银行境外综合金融服务业务旗舰平台，招银国际融资实施“立足香港，深植内地，面向全球”的发展战略。招银国际融资已逐步成为香港资本市场最为活跃且增长力强劲的金融机构之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725113131a6c0c9e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725113131a6c0c9e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554799343","title":"维立志博携4-1BB靶点全球首成药产品在港交所正式挂牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2554799343","media":"药智网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554799343?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:56","pubTimestamp":1753408568,"startTime":"0","endTime":"0","summary":"7月24日，维立志博在香港联合交易所主板正式挂牌上市，股票代码为9887.HK，预计募集资金总额可达1.89亿美元（含绿鞋），其中所得款项净额约46.0%将用于核心产品LBL-024的持续临床开发。该药在临床研究中展现强大的抗肿瘤活性，有望成为全球首个上市的4-1BB靶点药物。维立志博预计将在2026年提交BLA，并于2027年获得附条件批准，拿下全球首个EP-NEC治疗药物徽章。而LBL-024是进展最快的4-1BB抗体，有望成为全球首个，并在4-1BB抗体市场占据重要份额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725100148a6c09bc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725100148a6c09bc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887"],"gpt_icon":1},{"id":"2554530737","title":"“中国TCE第一股”开盘大涨126%！维立志博正式登陆港交所，多元布局领跑肿瘤免疫治疗2.0时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2554530737","media":"独角兽早知道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554530737?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:50","pubTimestamp":1753408200,"startTime":"0","endTime":"0","summary":"维立志博是一家临床阶段生物科技公司，专注于肿瘤、自身免疫性疾病及其他重大疾病新疗法的发现、开发及商业化。自2012年创立以来，维立志博始终专注于解决肿瘤、自身免疫性疾病等重大疾病领域未满足的临床需求。在IO 2.0领域，以PD-1/4-1BB双特异性抗体LBL-024为代表，通过多靶点调控激活抗肿瘤免疫。在TCE平台，维立志博则布局了LBL-034、LBL-033等双抗及LBL-051三抗，直接引导T细胞杀伤肿瘤。与此同时，LBL-024亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkzmt/2025-07-25/doc-infhrzcx1981666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09887","HEXmain"],"gpt_icon":1},{"id":"2554310732","title":"《股市简讯》中国生物科技公司维立志博香港“首秀”，盘中一度涨127%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554310732","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554310732?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:43","pubTimestamp":1753407835,"startTime":"0","endTime":"0","summary":"《股市简讯》中国生物科技公司维立志博香港“首秀”，盘中一度涨127%* 南京维立志博生物科技股份有限公司9887.HK周五香港首日挂牌开高107%后，盘中一度扩大涨幅至127%，触及79.6港元。* 这家专注于肿瘤及自身免疫性疾病疗法的公司此前以招股价区间顶端的每股35港元定价，香港首次公开发售集资12.9亿港元，公开发售及国际配售分别获近3,494倍及40倍超额认购。* 香港股市恒生指数.HSI盘中跌0.5%，恒生生物科技指数.HSHKBIO涨0.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nL4S3TM03Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1128548340","title":"异动解读 | 维立志博-B首日挂牌大涨115.71%，创新药企IPO获3494倍超额认购","url":"https://stock-news.laohu8.com/highlight/detail?id=1128548340","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128548340?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:32","pubTimestamp":1753407158,"startTime":"0","endTime":"0","summary":"7月25日，创新药企维立志博-B在港交所主板挂牌上市，盘中大涨115.71%，引发市场广泛关注。该公司此前公开发售部分获3494.78倍超额认购，最终以每股35港元的上限价格定价，募集资金净额约11.79亿港元。维立志博是一家专注于肿瘤免疫疗法的临床阶段生物科技公司，致力于开发突破性癌症疗法。尽管维立志博上市首日表现亮眼，但作为尚未盈利的生物科技公司，其未来发展仍面临研发风险、激烈的市场竞争以及商业化挑战。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09887"],"gpt_icon":0},{"id":"2554734627","title":"港股早评：三大指数低开 金融股回调 有色金属股、水泥股强势","url":"https://stock-news.laohu8.com/highlight/detail?id=2554734627","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554734627?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:28","pubTimestamp":1753406899,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["161032","01024","000819.SH","01772","89618","HTCD.SI","002466","TCHmain","BABA","MHImain","ALBmain","HSCEI","HSImain","600801","81024","YANG","HHImain","TTTN","02833","HSI","00700","07226","BIDU","HSTECH","03086","002460","JD","02233","06655","81299","KSTmain","159871","09887","161715","600585","03330","MCHmain","00914","81810","165316","01299","MIUmain","TCEHY","000979.SH","09696","09618","01810","HXXD.SI"],"gpt_icon":0},{"id":"2554734640","title":"“中国TCE第一股”在港交所挂牌上市，维立志博价值揭秘正当时","url":"https://stock-news.laohu8.com/highlight/detail?id=2554734640","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554734640?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:25","pubTimestamp":1753406700,"startTime":"0","endTime":"0","summary":"数据显示，上半年港股市场已完成35宗IPO项目，累计募资金额达959.29亿港元，较去年同期大幅增长758.8%，创下历史同期新高。值此之际，有着“中国TCE第一股”之称的维立志博于2025年7月25日在港交所主板正式挂牌上市，股票代码为09887。此次IPO，维立志博全球发售约3686万股股份，发售价为每股35港元，每手100股。日前，公司更是将TCE技术与ADC平台融合，推出创新产品LBL-058。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321772.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"“中国TCE第一股”在港交所挂牌上市，维立志博价值揭秘正当时","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887"],"gpt_icon":1},{"id":"2554773464","title":"新股首日 | 维立志博-B(09887.HK)首挂上市 早盘高开近107% 核心产品LBL-024为处于注册临床试验阶段的4-1BB靶向候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2554773464","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554773464?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:24","pubTimestamp":1753406693,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1576","BK1141","BK1583","09887","03347"],"gpt_icon":0},{"id":"1197788615","title":"新股首日｜维立志博-B大幅高开逾106%，中签一手赚3740港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197788615","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197788615?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:22","pubTimestamp":1753406530,"startTime":"0","endTime":"0","summary":"7月25日，$维立志博-B(09887)$首挂大幅高开逾106%，中签一手赚3740港元，总市值超136亿港元；此前公开发售阶段维立志博-B获3494.78倍认购，一手中签率0.27%，认购400手稳获一手。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2554734827","title":"一图看懂维立志博IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2554734827","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554734827?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:14","pubTimestamp":1753406071,"startTime":"0","endTime":"0","summary":"一图看懂维立志博IPO","market":"sg","thumbnail":"https://img2.gelonghui.com/f0fea-968eb6c9-e778-42b3-8eee-9c7741e6d403.png?guru_height=375&guru_width=540&guru_size=415615","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/f0fea-968eb6c9-e778-42b3-8eee-9c7741e6d403.png?guru_height=375&guru_width=540&guru_size=415615"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2542252","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["09887"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-07-25","current":-39.760016,"percent":1,"low":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"high":-39.760016,"avg":-39.760016,"sd":0,"marketCap":12652000240},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240}],"updateTime":1753571613298}}}